KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Current Deferred Tax Assets: 2012-2014

Historic Current Deferred Tax Assets for Regeneron Pharmaceuticals (REGN) over the last 3 years, with Dec 2014 value amounting to $46.2 million.

  • Regeneron Pharmaceuticals' Current Deferred Tax Assets rose 23.50% to $60.5 million in Q3 2015 from the same period last year, while for Sep 2015 it was $60.5 million, marking a year-over-year increase of 23.50%. This contributed to the annual value of $46.2 million for FY2014, which is 3.36% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Current Deferred Tax Assets stood at $46.2 million for FY2014, which was up 3.36% from $44.7 million recorded in FY2013.
  • Over the past 5 years, Regeneron Pharmaceuticals' Current Deferred Tax Assets peaked at $148.1 million during FY2012, and registered a low of $44.7 million during FY2013.
  • For the 3-year period, Regeneron Pharmaceuticals' Current Deferred Tax Assets averaged around $79.7 million, with its median value being $46.2 million (2014).
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Current Deferred Tax Assets crashed by 69.84% in 2013 and then grew by 3.36% in 2014.
  • Regeneron Pharmaceuticals' Current Deferred Tax Assets (Yearly) stood at $148.1 million in 2012, then slumped by 69.84% to $44.7 million in 2013, then grew by 3.36% to $46.2 million in 2014.